EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Perioperative Intravenous Lidocaine Infusion Versus Placebo for Opioid Consumption Reduction in Abdominal Surgery: A Systematic Review and Meta-Analysis

Chiamaka Serena Chima

The Operating Room Global Journal · 09.04.2026 · 2 (2)

DOI: 10.64573/torgj2604001 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift The Operating Room Global Journal, online erschienen am 09.04.2026. Verfasst von Chiamaka Serena Chima.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Postoperative opioid consumption after abdominal surgery contributes to delayed recovery, nausea, and long-term opioid dependence. Perioperative intravenous (IV) lidocaine infusion has been proposed as an opioid-sparing multimodal analgesic adjunct.

Methods

Following PRISMA 2020 guidelines, we searched PubMed, Embase, and ClinicalTrials.gov from inception to 15 March 2026. Eligible studies were randomised controlled trials comparing perioperative IV lidocaine infusion versus placebo in adult patients undergoing abdominal surgery under general anaesthesia. The primary outcome was cumulative postoperative opioid consumption at 24 and 48 hours. Secondary outcomes included pain scores, postoperative nausea and vomiting (PONV), length of hospital stay, and adverse events. Data were pooled using random-effects models; heterogeneity, risk of bias, and evidence quality were evaluated.

Results

52 RCTs (n = 3,812 patients) were included. Perioperative IV lidocaine reduced 24-hour opioid consumption (weighted mean difference -8.7 mg morphine equivalents, 95% CI -12.4 to -5.0; I2 = 68%) and 48-hour consumption (WMD -11.2 mg, 95% CI -15.8 to -6.6; I2 = 72%). Pain scores at rest and on movement were lower at all assessed time points. Time to first flatus and bowel movement decreased, PONV incidence was reduced (risk ratio 0.68, 95% CI 0.54-0.86), and hospital length of stay was shortened by 0.6 days.

Conclusions

Perioperative IV lidocaine infusion is an effective and safe opioid-sparing strategy that reduces postoperative opioid consumption, pain, and accelerates recovery after abdominal surgery. These findings support its integration into enhanced recovery after surgery (ERAS) protocols and multimodal analgesia regimens. Keywords: Lidocaine; Analgesic, Opioid; Abdominal Surgery; Opioid-Sparing

Zitieren

APA

Chima, C. S. (2026). Perioperative Intravenous Lidocaine Infusion Versus Placebo for Opioid Consumption Reduction in Abdominal Surgery: A Systematic Review and Meta-Analysis. The Operating Room Global Journal, 2(2). https://doi.org/10.64573/torgj2604001

Vancouver

Chima CS. Perioperative Intravenous Lidocaine Infusion Versus Placebo for Opioid Consumption Reduction in Abdominal Surgery: A Systematic Review and Meta-Analysis. The Operating Room Global Journal. 2026;2(2). doi:10.64573/torgj2604001

BibTeX
@article{Chima2026,
  author = {Chima, Chiamaka Serena},
  title = {Perioperative Intravenous Lidocaine Infusion Versus Placebo for Opioid Consumption Reduction in Abdominal Surgery: A Systematic Review and Meta-Analysis},
  journal = {The Operating Room Global Journal},
  year = {2026},
  volume = {2},
  number = {2},
  doi = {10.64573/torgj2604001}
}
Kostenlos starten →